Solanezumab
Solanezumab is a humanized monoclonal IgG1 antibody which is directed against the mid-domain of the Aβ peptide. By sequestering Aβ, shifting equilibria between different species of Aβ, and removing small soluble species of Aβ that are directly toxic to synaptic function, it may exert benefit.
Online Inquiry
| CAT# | 10-101-180 |
| CAS | 955085-14-0 |
| M.F/Formula | C6396H9922N1712O1996S42 |
| M.W/Mr. | 144000.1g/mol |
| Labeling Target | Amyloid precursor protein (APP) |
| Application | Solanezumab, or sola, binds the amyloid-β peptides that aggregate and form plaques in the brain that are an early pathological feature of Alzheimer's disease. |
| Areas of Interest | Neurological Disease |
Write a review
Ask a question
My Review for Solanezumab
Required fields are marked with *
×
Ask a Question for Solanezumab
Required fields are marked with *
×
If you have any peptide synthesis requirement in mind, please do not hesitate to contact us at . We will endeavor to provide highly satisfying products and services.
